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revention of Lesion Recurrence in Chronic Total
oronary Occlusions by Paclitaxel-Eluting Stents
erald S. Werner, MD, FACC, Andreas Krack, MD, Gero Schwarz, MD, Dirk Prochnau, MD,
tefan Betge, MD, Hans R. Figulla, MD
ena, Germany
OBJECTIVES The aim of this research was to assess the efficacy of paclitaxel-eluting stents in chronic total
coronary occlusions (CTO).
BACKGROUND Percutaneous coronary interventions for CTOs are characterized by a high target vessel failure
rate.
METHODS In 48 consecutive patients, paclitaxel-eluting stents (Taxus, Boston Scientific Corp., Natick,
Massachusetts) were implanted after successful recanalization of a CTO (duration2 weeks).
Patients underwent an angiography after 6 months and were followed clinically for 12
months. They were compared with 48 lesion- and risk-matched patients with CTOs treated
with bare metal stents (BMS). Primary clinical end point was the one-year incidence of major
adverse cardiac events (MACE) (death, myocardial infarction, repeat revascularization);
secondary end points were the rate of restenosis and re-occlusion.
RESULTS In-hospital MACE was 4.2% with Taxus, and 2.1% with BMS (p  NS). The one-year
MACE rate was 12.5% in the Taxus group, and 47.9% in the BMS group (p 0.001), which
was due to a reduced need for repeat revascularization. The angiographic restenosis rate was
8.3% with Taxus versus 51.1% with BMS (p  0.001). There was only one late re-occlusion
with Taxus (2.1%) as compared with 23.4% with BMS (p 0.005). The late loss was reduced
in the Taxus group by 84% as compared with BMS. All nonocclusive restenoses in the Taxus
group were focal and successfully treated by implanting an additional Taxus stent.
CONCLUSIONS The treatment of CTOs with a paclitaxel-eluting stent drastically reduces MACE and
restenosis, and almost eliminates re-occlusion, which is typically frequent with BMS in
CTOs. Chronic total coronary occlusion should be a preferred indication for drug-eluting
stents. (J Am Coll Cardiol 2004;44:2301–6) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.040Cardiology Foundation
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Mhronic total coronary occlusions (CTO) represent 10% of
esions treated by percutaneous coronary interventions
PCI) (1). The PCI in CTOs is characterized by a limited
rimary success rate (2) and a higher target vessel failure
TVF) rate even with routine use of coronary stents (3–8).
successfully recanalized CTO can improve left ventricular
LV) function and survival, but this is jeopardized by the
igh rate of re-occlusions (2,9,10). Diffusely diseased,
hronically occluded vessels require longer and multiple
tents, which adversely influence TVF (11–13). A solution
ould be drug-eluting stents, which proved effective in
omplex nonocclusive lesions (14–16). A registry analysis
uggests that drug-eluting stents may also be effective in
TOs (17), but there are no prospective angiographic
tudies or randomized trials. The present study is the first to
rospectively evaluate the safety and efficacy of a paclitaxel-
luting stent in CTOs and its effect on event-free survival
nd lesion recurrence in comparison with matched patients
ith CTOs treated with bare metal stents (BMS).
From the Clinic for Internal Medicine I, Friedrich-Schiller University Jena, Jena,
ermany.l
Manuscript received July 26, 2004; revised manuscript received August 27, 2004,
ccepted September 7, 2004.ETHODS
atients. A consecutive cohort of 48 patients with a
uccessfully recanalized CTO of a major coronary branch
diameter 2.0 mm) was enrolled and treated by implan-
ation of one or more polymer-based paclitaxel-eluting
tents (Taxus, Boston Scientific Corp., Natick, Massachu-
etts). The duration of the occlusion (Thrombolysis In
yocardial Infarction [TIMI] flow grade 0 or 1) was 2
eeks (median 6.3 months). Revascularization was indi-
ated by either chest pain or persistent occlusion after a prior
yocardial infarction (MI). Exclusion criteria were an LV
neurysm and TIMI flow grade 3 after stenting. The
atter lead to the exclusion of one patient. Written informed
onsent was obtained from all patients. All patients were
cheduled for angiography after 6 months and followed
linically for 12 months. No patient was lost to follow-up.
atched pair analysis. The Taxus group was compared
ith 48 matched patients with CTOs treated with BMS
Coroflex, B. Braun, Melsungen, Germany [18 patients];
estent2, Medtronic, Minneapolis, Minnesota [16 pa-
ients]; Jostent, Jomed AB, Helsingborg, Sweden [14 pa-
ients]). Matching criteria were history of diabetes, prior
I, diameter and number of implanted stents, lesionocation, and LV function. This BMS group was drawn
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Paclitaxel-Eluting Stents in Chronic Occlusions December 21, 2004:2301–6rom 148 consecutive patients treated within four years
efore availability of the Taxus stent. The matching was
one blinded to the angiographic outcome.
ngioplasty procedure. The recanalization was done as
escribed previously (13). All patients received aspirin
100 mg) and, additionally, clopidogrel (75 mg) for 4 weeks
fter BMS and for 6 months after Taxus stents. Glycopro-
ein IIb/IIIa antagonists were not used. The procedural
trategy was to cover the occlusion and adjacent dissections
ith one or more overlapping stents (Taxus stent length: 18,
4, 28, and 32 mm). A balloon-to-artery ratio of 1.1 with
nflation pressures of 12 to 16 atm was chosen. The goal was
residual stenosis 20% within the stent. The creatinine
inase was measured 12 to 24 h after the procedure.
uantitative coronary angiography. The occlusion length
as assessed from collateral filling and from the lesion
ength visible after the first balloon dilation. Quantitative
oronary angiography was done with a standard software
rogram (QCA for Research 1.3, PieMedical Imaging,
aastricht, the Netherlands) using the least foreshortening
rojection with the smallest minimum luminal diameter
MLD). The analysis included both the stent and 5 mm
roximal and distal of the stent edges. The late loss was
alculated at the site of the MLD at follow-up. The pattern
f restenosis was classified according to Mehran et al. (18).
n increase of the luminal diameter 25% of the reference
iameter at follow-up indicated coronary artery aneurysm
19). Biplane LV angiograms were obtained before PCI and
t follow-up and analyzed using a standard software pro-
ram (LVA 4.0, PieMedical Imaging).
tudy end points. The primary end point was the inci-
ence of major adverse cardiac events (MACE) within 12
onths after PCI, defined as cardiac death, periprocedural
nd late Q-wave MI, non–Q-wave MI defined by a creat-
nine kinase elevation above two times the upper reference
imit, and target lesion revascularization (TLR). Secondary
nd points were the binary restenosis rate defined as an
LD 50% of the reference diameter within the analyzed
egment, and the incidence of re-occlusion. Target vessel
ailure was defined as restenosis in the recanalized artery
rrespective of the treatment site.
tatistics. Data are given as mean values  SD. Group
ifferences were evaluated by analysis of variance or a
Abbreviations and Acronyms
BMS  bare metal stent
CTO  chronic total coronary occlusion
LV  left ventricle/ventricular
MACE  major adverse cardiac event
MI  myocardial infarction
MLD  minimum luminal diameter
PCI  percutaneous coronary intervention
TLR  target lesion revascularization
TVF  target vessel failurehi-square test, as appropriate. A Kaplan-Meier life-table Wnalysis was done with a log-rank test to compare the
ACE-free survival between groups. The sample size was
alculated to achieve a statistical power of 0.8 with an
ssumed MACE in BMS of 50% (13) and an expected
elative reduction of 50% by the paclitaxel-eluting stent. A
evel of p 0.05 was considered significant. All calculations
ere done with SPSS for Windows (SPSS Version 11.5,
PSS Inc., Chicago, Illinois).
ESULTS
linical and procedural characteristics. The clinical char-
cteristics in both groups were comparable (Table 1).
ne-third of patients had diabetes. The procedural data
ere well-matched (Table 2). The occlusion duration was
3 months in 70%. The occlusion length was 17 13 mm,
nd the total stent length was more than double the
cclusion length in both groups.
uantitative angiographic analysis. The baseline angio-
raphic parameters were similar in both groups (Table 2).
ne patient in the Taxus group had died before follow-up
ngiography. At follow-up after 5.2  1.5 months, the
LD in the Taxus group was significantly larger than in the
MS group (Fig. 1). In the Taxus group, the late loss and
he binary restenosis rate were reduced by 84%, and late
e-occlusion by 91% as compared with BMS (Table 2). All
VF in the Taxus group occurred with a single stent,
nrelated to stent length, whereas, in the BMS group, TVF
as 38% with a single stent, and 71% with 2 stents.
In the Taxus group, but not in the BMS group, a
oderate enlargement of the lumen within the stent was
bserved in three patients (4.2%) at follow-up, suggesting
ositive remodeling. One of these patients had a restenosis
t the opposite edge of the stent; after repeat PCI there was
o progression of the lumen enlargement at further
ollow-up (Fig. 2).
cute and long-term clinical events. Elevation of creati-
ine kinase without symptoms was the only acute MACE
Table 3). No subacute stent thrombosis was observed.
able 1. Clinical Data of Patients
Taxus
(n  48)
BMS
(n  48)
p
Value
ge (yrs) 63.1  10.7 65.0  7.9 0.31
ale gender (%) 79 74 0.51
iabetes (%) 33 29 0.58
ypertension (%) 81 76 0.50
ypercholesterolemia (%) 79 73 0.52
urrent smoker (%) 29 23 0.49
rior myocardial infarction (%) 42 47 0.61
umber of diseased arteries 2.0  0.7 1.8  0.7 0.34
CS angina score (1/2/3/4) (%) 15/33/52/0 8/37/55/0 0.61
jection fraction 0.67  0.16 0.68  0.15 0.78
ipid-lowering therapy (%) 85 79 0.42
CE inhibitors (%) 85 75 0.20
ata are mean values  SD or %.
ACE  angiotensin-converting enzyme; BMS  bare metal stent; CCS 
anadian Cardiovascular Society.ithin one year, one patient had died in the Taxus group,
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December 21, 2004:2301–6 Paclitaxel-Eluting Stents in Chronic Occlusionsnd two in the BMS group. These three patients had
everely impaired LV function. The MACE-free survival
as higher in the Taxus group (12.4% vs. 47.9%; p 0.001)
Fig. 3) due to a reduced TLR (Table 3).
nfluence of diabetes mellitus. In diabetic patients treated
ith BMS, the TVF rate was almost double that in
ondiabetic patients (64.3% vs. 35.3%). In contrast, there
as no influence of diabetes mellitus on TVF rate in the
axus group (Table 4). The advantage of the Taxus stents
ver BMS was significant both in diabetic and nondiabetic
atients.
reatment of lesion recurrence. Target vessel failure in
he BMS group was focal in 38%, diffuse in 16%, and
Table 2. Baseline Procedural Characteristics an
Duration of occlusion (median/months)
Duration of CTO 3 months (%)
Occluded artery
Left anterior descending artery (%)
Right coronary artery (%)
Left circumflex artery (%)
Total fluoroscopic time (min)
Length of occlusion (mm)
Number of stents
Stent length (mm)
Final balloon diameter (mm)
Reference diameter (mm)
MLD post (mm)
MLD follow-up (mm)
Diameter stenosis post (%)
Diameter stenosis follow-up (%)
Late loss (mm)
Binary restenosis (%)
Re-occlusion (%)
Follow-up time (days)
Data are mean values  SD or %. In the Taxus group, one
BMS  bare metal stent; CTO  chronic total coronary o
stenting.
igure 1. Cumulative distribution of minimum luminal diameter after
rocedure and at follow-up with paclitaxel-eluting (Taxus) and bare metal
tents (BMS). Open squares  post-procedure Taxus; open circles s
ollow-up Taxus; solid squares  post-procedure BMS; solid circles 
ollow-up BMS.cclusive in 46%. In the Taxus group, one patient had
e-occlusion, which was treated medically. The three non-
cclusive TVFs were focal and located at the stent edge.
hey received an additional Taxus stent. A subsequent
ngiography within four to six months showed no recurrent
estenosis.
ISCUSSION
he present study was done in a “real world” cohort of
atients with CTOs without lesion-related exclusion crite-
ia. They represent lesions with the highest risk of TVF, but
hey are excluded from recent randomized trials of drug-
luting stents (14–16,20). We could show a considerable
linical benefit of a paclitaxel-eluting stent in CTOs with
eduction of MACE and TVF by more than 80% as
ompared with a matched group treated with BMS.
isk profile of study group. No selection criteria regarding
esion length and angiographic characteristics were applied
ncluding also small vessels of 2.5 mm. This explains the
igher TVF rate in the BMS group as compared with
revious studies applying more restrictive inclusion criteria
3,4). However, it was comparable with the largest random-
zed study in CTOs with less restrictive inclusion criteria
5). The comparison with randomized studies of BMS in
TOs (Table 5) underscores that the present study con-
isted of lesions with a higher risk profile, notably more
iabetes, and smaller reference diameters with smaller
LD after the procedure, which are predictors of stent
estenosis (21).
afety and efficacy of paclitaxel-eluting stents in CTOs. The
axus group showed a substantially improved MACE-free
uantitative Angiography
xus
48)
BMS
(n  48) p Value
.5 5.6 0.70
65 0.42
0.38
33
61
6
13.6 27.5  10.6 0.72
13 16  12 0.63
0.9 1.7  1.0 0.91
19 36  21 0.33
0.38 3.04  0.44 0.26
0.47 2.65  0.65 0.51
0.36 2.16  0.60 0.32
0.59 1.00  0.73 0.001
12 15  10 0.17
20 59  28 0.001
0.62 1.21  0.70 0.001
.3 51.1 0.001
.1 23.4 0.003
40 153  47 0.42
t had died before follow-up angiography.
on; MLD  minimum luminal diameter; post  result afterd Q
Ta
(n 
6
73
36
56
8
26.6 
18 
1.7 
40 
2.95 
2.57
2.26 
2.05 
11 
20
0.19 
8
2
160 
patienurvival due to a reduced TLR without increased risk of
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Paclitaxel-Eluting Stents in Chronic Occlusions December 21, 2004:2301–6eriprocedural MI or subacute stent thrombosis as com-
ared with BMS. The late loss with this paclitaxel-eluting
tent was in the range observed in nonocclusive lesions (16),
ut the clinical benefit was even greater in CTOs. The few
ocal restenoses at the edges of the stented segment indicate
igure 2. Examples from the Taxus group. (A)Occlusion location indicated by
atient 1 (age 59 years, male) right coronary artery (RCA) occlusion (duration
nterior descending coronary artery (LAD) occlusion (seven months), one 28-m
4 years, female, diabetes) ostial LAD occlusion (eight months), two stents (
8-mm stent. (C) Irregular moderate positive remodeling at follow-up (arr
ecurrence four months later, no progression of the negative remodeling (D,
able 3. Hierarchical Incidence of MACE During
ospitalization and 12-Month Follow-Up in Patients With
uccessful Recanalization of a CTO
Taxus
(n  48)
BMS
(n  48)
ospitalization
Death 0 0
Q-wave MI 0 0
Non–Q-wave MI† 4.2 (2) 2.1 (1)
Subacute stent thrombosis 0 0
ollow-up
Death 2.1 (1) 4.2 (2)
Q-wave MI 0 0
Repeat PCI 6.3 (3) 31.9 (15)*
CABG 0 12.8 (6)
otal MACE 12.5 (6) 47.9 (23)*
Comparison between the groups: p  0.001; †non–Q-wave MI defined by elevation
f creatine kinase (two times upper limit of normal) within 24 h of recanalization.
requency of events (%) with number of patients in parentheses.
BMS  bars metal stent; CABG  coronary artery bypass grafting; CTO f
(
hronic total coronary occlusion; MACE  major adverse cardiac event; MI 
yocardial infarction; PCI  percutaneous coronary intervention.hat a liberal stent coverage of the segment adjacent to the
riginal occlusion might be preferred in these diffusely
iseased arteries.
Positive remodeling with incomplete stent apposition
nd development of coronary artery aneurysms has been a
oncern with drug-eluting stents (22). Recent trials did
head; (B) after stent implantation (stents indicated by arrows); (C) follow-up.
months), three stents (total length 72 mm). Patient 2 (age 51 years, male) left
nt. Moderate positive remodeling at follow-up (C, arrowhead). Patient 3 (age
ength 44 mm). Patient 4 (age 54 years, male, diabetes) RCA occlusion, one
nd focal restenosis proximal (arrowhead). After additional Taxus stent, no
).
igure 3. Kaplan-Meier curves of major adverse cardiac event (MACE)-arrow
nine
m ste
total lree survival; p value for log-rank comparison of Taxus and bare metal stent
BMS) groups.
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December 21, 2004:2301–6 Paclitaxel-Eluting Stents in Chronic Occlusionsot show an increased risk of coronary artery aneurysm
ith the Taxus stent (16,20). In our study, 3 of 48
atients (6%) had a moderate increase of luminal diam-
ter at follow-up not reaching the angiographic criteria of
oronary aneurysm (19). We did not perform intravascu-
ar ultrasound, which could have clarified the morphol-
gy. Our observation could be accidental in a limited
umber of patients, and future studies with intravascular
ltrasound could provide a larger database to assess the
isk for coronary aneurysms in CTOs.
tudy limitations. The size of this study is comparable to
revious studies of BMS in CTOs (Table 5). The high TVF
ith BMS provides an adequate statistical power to detect
he clinical and angiographic benefit of drug-eluting stents.
he comparison with a matched control group is less
onvincing than a double-blind randomized approach, but it
s superior to non-matched registries. Furthermore, the
ingle-center approach ascertains uniform technical perfor-
ance of the PCI in both study groups. The MACE rate
as mainly determined by TLR, and this could be influ-
nced by the fact that we performed an angiographic
ollow-up in all patients (23). But the decision to revascu-
arize a CTO is not only based on clinical symptoms but also
n prognostic considerations, and angiographic control
ppears justified (2,10).
linical implications. Our study, together with recent
egistry data on a sirolimus-eluting stent system (17),
upports that drug-eluting stents are a major advancement
or the treatment of CTOs. In view of these data and the
roven advantage of drug-eluting stents in nonocclusive
esions, a randomized trial of drug-eluting stents versus
MS in CTOs may not be required. However, the issue of
ore extensive stent coverage versus more selective place-
ent in the area of the occluded lesion and the comparison
f different drug-eluting stents should be addressed by a
andomized approach.
eprint requests and correspondence: Dr. Gerald S. Werner,
linik für Innere Medizin I, Friedrich-Schiller-Universität,
rlanger Allee 101, D-07740 Jena, Germany. E-mail: gerald.
able 4. Target Vessel Failure After Recanalization of a CTO
n Patients With and Without Diabetes Mellitus
Taxus BMS
atients with diabetes mellitus 16 14
TVF 6.3 (1)* 64.3 (9)
MACE 6.3 (1)* 64.3 (9)
atients without diabetes mellitus 32 34
TVF 9.4 (3)† 35.3 (12)
MACE 15.6 (5)† 41.2 (14)
requency of events (%) with number of patients in parentheses. Comparison between
axus and BMS group: *p  0.001; †p  0.05.
BMS  base metal stent; CTO  chronic total coronary occlusion; MACE 
ajor adverse cardiac event; TVF  target vessel failure.erner@med.uni-jena.de. Ta
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